A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

• Status: Recruiting
• Trial end date: 2024-10-31
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MBQ Pharma
• Collaborator: Congressionally Directed Medical Research Programs

Criteria

Key Inclusion Criteria:

• The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.

• Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.

• Participants with known brain metastases may be eligible if specific conditions are met.

• Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.

• Are able to swallow capsules twice daily.

Key Exclusion Criteria:

• The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.

• Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.

• Females who are pregnant or breastfeeding.

• Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 30 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.

• Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 30 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.

• Active malignancies other than advanced breast cancer will be excluded from the study.